W
NBIX icon

WealthCollab’s Neurocrine Biosciences NBIX Stock Holding History

WealthCollab’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.74K Hold
40
– – ﹤0.01% 658
2026
Q1 		$5.27K Hold
40
– – ﹤0.01% 672
2025
Q4 		$5.67K Hold
40
– – ﹤0.01% 701
2025
Q3 		$5.62K Hold
40
– – ﹤0.01% 654
2025
Q2 		$5.03K Buy
+40
New +$4.59K ﹤0.01% 638
2024
Q3 		– Sell
-39
Closed -$5.37K – 914
2024
Q2 		$5.37K Hold
39
– – ﹤0.01% 573
2024
Q1 		$5.38K Buy
+39
New +$5.33K ﹤0.01% 574

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WealthCollab's NBIX Position: Q2 2026 in Review

WealthCollab held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 40 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

WealthCollab first reported a position in NBIX in Q1 2024 and has held it in 7 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • WealthCollab held 40 shares of Neurocrine Biosciences worth $6.74K as of Q2 2026.
  • WealthCollab left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of WealthCollab's portfolio in Q2 2026, its #658 holding.
  • WealthCollab first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 7 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on WealthCollab's 13F filing for Q2 2026, filed 10 Aug 2026.